Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
PLoS Pathog ; 7(9): e1002277, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21980294

ABSTRACT

Binding of herpes simplex virus (HSV) glycoprotein D (gD) to a cell surface receptor is required to trigger membrane fusion during entry into host cells. Nectin-1 is a cell adhesion molecule and the main HSV receptor in neurons and epithelial cells. We report the structure of gD bound to nectin-1 determined by x-ray crystallography to 4.0 Å resolution. The structure reveals that the nectin-1 binding site on gD differs from the binding site of the HVEM receptor. A surface on the first Ig-domain of nectin-1, which mediates homophilic interactions of Ig-like cell adhesion molecules, buries an area composed by residues from both the gD N- and C-terminal extensions. Phenylalanine 129, at the tip of the loop connecting ß-strands F and G of nectin-1, protrudes into a groove on gD, which is otherwise occupied by C-terminal residues in the unliganded gD and by N-terminal residues in the gD/HVEM complex. Notably, mutation of Phe129 to alanine prevents nectin-1 binding to gD and HSV entry. Together these data are consistent with previous studies showing that gD disrupts the normal nectin-1 homophilic interactions. Furthermore, the structure of the complex supports a model in which gD-receptor binding triggers HSV entry through receptor-mediated displacement of the gD C-terminal region.


Subject(s)
Cell Adhesion Molecules/chemistry , Herpesvirus 1, Human/chemistry , Receptors, Virus/chemistry , Viral Envelope Proteins/chemistry , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Herpesvirus 1, Human/physiology , Humans , Nectins , Protein Binding , Protein Structure, Quaternary , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Virus/genetics , Receptors, Virus/metabolism , Structure-Activity Relationship , Viral Envelope Proteins/genetics , Viral Envelope Proteins/metabolism , Virus Internalization
2.
Clin Vaccine Immunol ; 17(8): 1282-90, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20610661

ABSTRACT

Accurate determination of diphtheria toxin antibodies is of value in determining the rates of immunity within broad populations or the immune status of individuals who may be at risk of infection, by assessing responses to vaccination and immunization schedule efficacy. Here we report the results of an external quality assessment (EQA) study for diphtheria serology, performed within the dedicated surveillance network DIPNET. Twelve national laboratories from 11 European countries participated by testing a standard panel of 150 sera using their current routine method: Vero cell neutralization test (NT), double-antigen enzyme-linked immunosorbent assay (ELISA; DAE), dual double-antigen time-resolved fluorescence immunoassay (dDA-DELFIA), passive hemagglutination assay (PHA), toxin binding inhibition assay (ToBI), and in-house or commercial ELISAs. The objective of the study was not to identify the best assay, as the advantages and drawbacks of methods used were known, but to verify if laboratories using their routine method would have categorized (as negative, equivocal, or positive) a serum sample in the same way. The performance of each laboratory was determined by comparing its results on a quantitative and qualitative basis to NT results from a single reference laboratory, as this test is considered the in vitro "gold standard." The performance of laboratories using NT was generally very good, while the laboratories' performance using other in vitro methods was variable. Laboratories using ELISA and PHA performed less well than those using DAE, dDA-DELFIA, or ToBI. EQA is important for both laboratories that use in vitro nonstandardized methods and those that use commercial ELISA kits.


Subject(s)
Diphtheria Antitoxin/blood , Quality Assurance, Health Care/methods , Serologic Tests/standards , Serum/immunology , Europe , Humans , Reference Standards
3.
J Biol Chem ; 283(39): 26694-704, 2008 Sep 26.
Article in English | MEDLINE | ID: mdl-18614528

ABSTRACT

Histone deacetylases (HDACs) regulate chromatin status and gene expression, and their inhibition is of significant therapeutic interest. To date, no biological substrate for class IIa HDACs has been identified, and only low activity on acetylated lysines has been demonstrated. Here, we describe inhibitor-bound and inhibitor-free structures of the histone deacetylase-4 catalytic domain (HDAC4cd) and of an HDAC4cd active site mutant with enhanced enzymatic activity toward acetylated lysines. The structures presented, coupled with activity data, provide the molecular basis for the intrinsically low enzymatic activity of class IIa HDACs toward acetylated lysines and reveal active site features that may guide the design of class-specific inhibitors. In addition, these structures reveal a conformationally flexible structural zinc-binding domain conserved in all class IIa enzymes. Importantly, either the mutation of residues coordinating the structural zinc ion or the binding of a class IIa selective inhibitor prevented the association of HDAC4 with the N-CoR.HDAC3 repressor complex. Together, these data suggest a key role of the structural zinc-binding domain in the regulation of class IIa HDAC functions.


Subject(s)
Histone Deacetylases/chemistry , Repressor Proteins/chemistry , Zinc/chemistry , Acetylation , Binding Sites/physiology , Cell Line , Chromatin/metabolism , Chromatin Assembly and Disassembly/physiology , Crystallography, X-Ray , Histone Deacetylases/metabolism , Humans , Protein Binding/physiology , Protein Structure, Tertiary/physiology , Repressor Proteins/metabolism , Zinc/metabolism
4.
Anal Biochem ; 377(2): 267-9, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18381195

ABSTRACT

Histone deacetylase 4 (HDAC4) is a histone deacetylase profoundly involved in cell differentiation and in the pathogenesis of cancer. The histone deacetylase inhibitors are a new, promising class of anticancer agents. The screening of molecular interactions involving determination of the affinity of drug candidates is an integral part of the drug discovery process. Here we report the development of an assay using surface plasmon resonance for the analysis of HDAC4-small molecule interactions. We describe a new cloning and purification strategy that can be used to set up surface plasmon resonance experiments with other recombinant proteins.


Subject(s)
Histone Deacetylases/metabolism , Surface Plasmon Resonance , Dose-Response Relationship, Drug , Enzyme Inhibitors/metabolism , Enzyme Inhibitors/pharmacology , Enzymes, Immobilized/antagonists & inhibitors , Enzymes, Immobilized/metabolism , Histone Deacetylase Inhibitors , Ketones/chemistry , Ketones/metabolism , Protein Binding , Recombinant Proteins/antagonists & inhibitors , Recombinant Proteins/metabolism
5.
Nat Struct Mol Biol ; 13(8): 740-7, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16862157

ABSTRACT

Elicitation of potent and broadly neutralizing antibodies is an important goal in designing an effective human immunodeficiency virus-1 (HIV-1) vaccine. The HIV-1 gp41 inner-core trimer represents a functionally and structurally conserved target for therapeutics. Here we report the 2.0-A-resolution crystal structure of the complex between the antigen-binding fragment of D5, an HIV-1 cross-neutralizing antibody, and 5-helix, a gp41 inner-core mimetic. Both binding and neutralization depend on residues in the D5 CDR H2 loop protruding into the conserved gp41 hydrophobic pocket, as well as a large pocket in D5 surrounding core gp41 residues. Kinetic analysis of D5 mutants with perturbed D5-gp41 interactions suggests that D5 persistence at the fusion intermediate is crucial for neutralization. Thus, our data validate the gp41 N-peptide trimer fusion intermediate as a target for neutralizing antibodies and provide a template for identification of more potent and broadly neutralizing molecules.


Subject(s)
Antibodies, Monoclonal/chemistry , HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Antibodies, Monoclonal/metabolism , Cells, Cultured , Crystallography, X-Ray , HIV Envelope Protein gp41/metabolism , HIV-1/metabolism , Humans , Hydrophobic and Hydrophilic Interactions , Leucine/chemistry , Models, Molecular , Mutation , Neutralization Tests , Protein Conformation , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Tryptophan/chemistry
6.
Bioinformatics ; 20(18): 3652-3, 2004 Dec 12.
Article in English | MEDLINE | ID: mdl-15247096

ABSTRACT

SUMMARY: The searchable mutant database PLPMDB has been developed to provide rapid and simple access to relevant mutant information on pyridoxal-5'-phosphate dependent enzymes. All data have been extracted from publications and publicly available databases, then organized in a relational database to enable searching via a web-based search form. The current version of PLPMDB contains 688 mutants described in 220 research papers. The database is a useful tool for planning mutant experiments and for interpretation of information from such experiments. AVAILABILITY: PLPMDB is freely accessible from http://www.studiofmp.com/plpmdb/index.htm.


Subject(s)
Database Management Systems , Databases, Protein , Enzymes/chemistry , Information Storage and Retrieval/methods , Mutation , Pyridoxal Phosphate/chemistry , Sequence Analysis, Protein/methods , Enzymes/metabolism , Information Dissemination/methods , Internet , Pyridoxal Phosphate/metabolism , Sequence Alignment/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...